CAR-T Therapy
Cross-source consensus on CAR-T Therapy from 1 sources and 4 claims.
1 sources · 4 claims
Uses
Evidence quality
Other
Highlighted claims
- The study includes standard-of-care CD19-directed CAR-T products tisagenlecleucel and axicabtagene. — Longitudinal real-world surveillance of infection outcomes in CAR-T and bispecific therapy recipients: the CLARITY study protocol
- Existing CAR-T trial data are insufficient for infection surveillance because they incompletely report outcomes and often lack pathogen-level detail. — Longitudinal real-world surveillance of infection outcomes in CAR-T and bispecific therapy recipients: the CLARITY study protocol
- Early-phase CAR-T trials commonly provide only six months of safety follow-up. — Longitudinal real-world surveillance of infection outcomes in CAR-T and bispecific therapy recipients: the CLARITY study protocol
- BCMA-directed CAR-T therapy will be added under the existing ethics approval when it becomes standard of care for myeloma. — Longitudinal real-world surveillance of infection outcomes in CAR-T and bispecific therapy recipients: the CLARITY study protocol